日英幹細胞ワークショップをiCeMSで開催 | UK-Japan Workshop on Stem Cells: Building a Better Environment for Application
ワークショップ2日目に参加した関係者ら（京都大学iCeMS本館2F交流ラウンジ）
2013年3月8日
英国総領事館と内閣府最先端・次世代研究開発支援（NEXT）プログラム研究課題「幹細胞科学技術の統合的イノベーション・マネジメント研究と人材育成・事業化支援」（研究者：仙石慎太郎iCeMS准教授）は7日と8日、京都大学iCeMS及びNPO法人京都ＳＭＩと協力し、胚性幹（ES）細胞や人工多能性幹（iPS）細胞などの実用化に向けた様々な課題について議論するワークショップを、iCeMSで開催しました。イギリス、日本、中国、台湾、韓国の大学、企業、政府機関などから2日間で約50名が参加し、京都大学からはiCeMS、iPS細胞研究所（CiRA）、再生医科学研究所の研究者などが登壇しました。
ワークショップはES/iPS細胞などの研究進捗、知的財産と商業化、規制といったテーマごとに区切られ、それぞれの専門家が意見を交わしました。幹細胞研究に係る倫理や情報伝達・対話については、一般市民の理解と参加が特に重要との観点から、メディア関係者も参加できるセッションとして公開されました。
今回このメンバーで集まった意義について、仙石准教授は「幹細胞科学技術の多様な側面を支え、またリードする当事者同士が、国や組織の枠を超えて自発的に議論する場が日本には乏しかった。倫理・規制・イノベーションにおける機能的な協業には、今回学んだイギリスの先行事例などが非常に参考になる。こうした場が日本にも定着するよう、他の国・地域とも連携し、これからも様々な模索と積極的な働きかけを続けていきたい」としています。
プログラム
1日目（2013年3月7日）
| Speakers | Titles |
|---|---|
| Mr Ed Thomson, Science & Innovation Consul, British Consulate-General, Osaka | Opening remarks |
| Session 1: Updates on Stem Cell Research [Moderator: Dr Shintaro Sengoku, WPI-iCeMS, Kyoto University] | |
| Dr Rob Buckle, Director of Science Programmes, Medical Research Council (MRC) | Overview of UK stem cell and regenerative medicine |
| Dr Kazuhiro Aiba, Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University | Clinical-grade cardiomyocytes derived from human pluripotent stem cells |
| Dr Shin Kaneko, Center for iPS Cell Research and Application (CiRA), Kyoto University | Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation |
| Dr Masayo Takahashi, Laboratory for Retinal Regeneration, Center for Developmental Biology (CDB), RIKEN | Application of iPS cells for retinal diseases |
| Session 2: Stem Cell Research: IP and Commercialisation [Moderator: Prof Takashi Asada, WPI-iCeMS, Kyoto University] | |
| Mr Atsushi Onodera, Legal Affairs & IP, Center for iPS Cell Research and Application (CiRA), Kyoto University | Our mission and approach through IPR for disseminating iPSC technology, for contributing society |
| Dr Chikafumi Yokoyama, President & CEO, ReproCELL, Inc. | |
| Dr Koichi Sumikura, Director of Research, 2nd Theory-Oriented Research Group, National Institute of Science and Technology Policy (NISTEP), Ministry of Education, Culture, Sports, Science and Technology (MEXT); Associate Professor, National Graduate Institute of Policy Studies (GRIPS) | Issues on patentability of stem cells |
| Dr Shintaro Sengoku, Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University | Global competencies from regional stem cell research: a bibliometric approach for investigating and forecasting research trends |
| Prof Hong-Nerng Ho, Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University | The stem cell intellectual property and commercialisation in Taiwan |
| Prof Chris Mason, Stem Cell & Regenerative Medicine Bioprocessing Unit, Advanced Centre for Biochemical Engineering, University College London | Establishing a multibillion-dollar cell therapy industry requires a simple A,B,C approach - Academics, Businesspeople & Clinicians working together to integrate discovery research, clinical translation and commercialization into a seamless process |
2日目（2013年3月8日）
| Speakers | Titles |
|---|---|
| Session 3: Stem Cell Research: Regulation [Moderator: Dr Sarah Chan, University of Manchester] | |
| Mr Douglas Sipp, Science Policy and Ethics Studies Unit, Center for Developmental Biology (CDB), RIKEN | Access paths for developmental-stage stem cell products |
| Prof Takashi Aoi, Center for iPS Cell Research and Application (CiRA), Kyoto University | Development of iPSC-based cell therapy in Japan |
| Dr Rob Buckle, Director of Science Programmes, Medical Research Council (MRC) | UK regulation of human pluripotent stem cell research — this will encompass the UK Code of Practice, its rationale and implementation |
| Prof Masayuki Yamato, Institute of Advanced Biomedical Engineering and Science, TWIns, Tokyo Women's Medical University | Need of the legal framework for the use of human tissue |
| Dr Akifumi Matsuyama, Department of Somatic Stem Cell Therapy and Health Policy, Foundation for Biomedical Research and Innovation (FBRI) | Regulatory Frameworks of Regenerative Medicine in Japan |
| Dr Glyn Stacey, Division of Cell Biology and Imaging The UK Stem Cell Bank | Preparing human pluripotent stem cells for cell therapy |
| Session 4: Stem Cell Research: Ethics and Communication [open to media] [Moderator: Mr Douglas Sipp, RIKEN CDB] | |
| Dr Sarah Chan, Institute for Science, Ethics and Innovation(iSEI), The University of Manchester | Emerging Issues in Stem Cell Ethics |
| Prof Kazuto Kato, Graduate School of Medicine, Osaka University | |
| Prof Soojung Kim, Department of Medical Humanities & Social Sciences, School of Medicine, The Catholic University of Korea | Ethical Issues Related to Stem Cell Research & Treatment in Korea |
| Prof Clare Blackburn, Tissue Stem Cell Biology, MRC Centre for Regenerative Medicine, University of Edinburgh | Communication and engagement with stem cell research: the EuroStemCell model |
| Mr Douglas Sipp, Science Policy and Ethics Studies Unit, Center for Developmental Biology (CDB), RIKEN | Dual markets for stem cell interventions in Japan |
| Prof Margaret Sleeboom-Faulkner, Centre for Bionetworking, University of Sussex | Translocal Stem Cell Experimentation: Why 'the unethical' is 'acceptable' |
| Session 5: Summary Discussion [Moderator: Dr Rob Buckle, Medical Research Council (MRC)] | |
| Discussion | |
| Dr Shintaro Sengoku, Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University | Closing remarks |
写真
左から、開会挨拶をする英国総領事館エド・トムソン領事（科学技術担当）と、閉会挨拶をする仙石准教授
ワークショップ中の様子